Aetio Biotech

Aetio Biotherapy is a clinical-stage biotechnology company headquartered in Dallas, Texas, specializing in the development of next-generation immunotherapies for cancer. Founded in 2018, the company utilizes a proprietary protein prodrug technology platform to engineer locally activated antibody and cytokine fusion proteins designed to minimize systemic toxicity while maximizing anti-tumor activity. Its pipeline features novel candidates such as Bis5, a PD-1/TIM-3 bispecific antibody currently in Phase 1 clinical trials, and various pre-clinical programs targeting regulatory T cell (Treg) depletion and tumor-specific cytokine delivery. Aetio Biotherapy operates through strategic partnerships with Livzon Pharmaceutical Group and maintains research collaborations with UT Southwestern Medical Center.